Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Going to add to ibox CHU's list
added to board trix
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23724264
RE TAM trust...
1. The TAM Irrevocable Trust is an irrevocable trust for the benefit of certain family members of Mr. Carl Palmer. Mr. Palmer disclaims any beneficial ownership or interest in this Trust. Cari Beck, his daughter, is the Trustee of the Trust and has total beneficiary rights, including all voting rights and investment power as the Trustee. The Trust is held in her name (50%) as well as that of Lindsay Helvey (25%) and Casey Helvey (25%), both granddaughters.
Convertible Promissory Notes...
Immediately following the closing of the Acquisition, an aggregate of $680,650 in INCA debt was converted by non-affiliates into 26,063,750 shares of its Common Stock at a conversion ratio of $.026 per share.
(WOWZA) and this after 2 r/s before they ever gave shares.
many more
http://investorshub.advfn.com/boards/read_msg.asp?message_id=23692204
re: filing from IDGI today...
As of June 30, 2007, the Company’s consolidated cash balance was $301,765. Outstanding debt as of June 30, 2007 totaled $6,064,000 including approximately $3,770,000 in pre-acquisition debt.
The Company’s working capital deficit as of June 30, 2007 was $5,365,961.
S2 has been operated as a private company that is not subject to Sarbanes-Oxley regulations and, therefore, may lack the financial controls and procedures of public companies.
On April 3, 2007, INCA issued a Single Payment Promissory Note to Michael J. Rosenblatt for $100,000. The note accrues interest at a rate of 15% per annum and is due on April 2, 2008.
In conjunction with the Acquisition on May 21, 2007, INCA assumed and reissued a Convertible Promissory Note with an effective date of November 20, 2006 to George D. Schaefer in the amount of $100,000 with a due date of May 15, 2007 (the “Note”). The due date of the Note was verbally extended by mutual agreement of the parties to September 30, 2007. The Note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s common stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. In conjunction with the Note, the Company issued Warrants to purchase 200,000 shares of common stock of INCA for an exercise price of $0.50 per share. The Warrants expire on October 31, 2009. The shares underlying the Note and the Warrants are covered under a registration rights agreement.
In conjunction with the Acquisition on May 21, 2007, INCA assumed and reissued a Convertible Promissory Note with an effective date of November 20, 2006 to Ronald B. and Kathleen A Johnson in the amount of $125,000 with a due date of May 15, 2007 (the “Note”). The due date of the Note was verbally extended by mutual agreement of the parties to September 30, 2007. The Note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. In conjunction with the Note, the Company issued Warrants to purchase 250,000 shares of common stock of INCA for an exercise price of $0.50 per share. The Warrants expire on October 31, 2009. The shares underlying the Note and the Warrants are covered under a registration rights agreement.
In conjunction with the Acquisition on May 21, 2007, INCA assumed and reissued a Convertible Promissory Note with an effective date of November 20, 2006 to John L. Coleman in the amount of $100,000 with a due date of September 30, 2007 (the “Note”). The note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. In conjunction with the Note, the Company issued Warrants to purchase 200,000 shares of common stock of INCA for an exercise price of $0.50 per share. The Warrants expire on October 31, 2009. The shares underlying the Note and the Warrants are covered under a registration rights agreement.
In conjunction with the Acquisition on May 21, 2007, INCA assumed and reissued a Convertible Promissory Note with an effective date of May 16, 2006 to George D. Schaefer in the amount of $100,000 with a due date of October 31, 2007. The note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. In conjunction with the Note, George D. Schaefer was issued Warrants to purchase 200,000 shares of common stock of S2 New York for an exercise price of $0.50 per share. The Warrants expire on October 31, 2009. The shares underlying the Note and the Warrants are covered under a registration rights agreement.
In conjunction with the Acquisition on May 21, 2007, INCA assumed and reissued a Convertible Promissory Note with an effective date of May 16, 2006 to Robert J. Smith in the amount of $75,000 with a due date of October 31, 2007. The note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. In conjunction with the Note, Robert J. Smith was issued Warrants to purchase 150,000 shares of common stock of INCA for an exercise price of $0.50 per share. The Warrants expire on October 31, 2009. The shares underlying the Note and the Warrants are covered under a registration rights agreement.
On June 20, 2007, INCA issued a Convertible Promissory Note to Plato & Associates, LLC for $200,000 with a due date of June 20, 2008. The note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. The shares underlying the Note are covered under a registration rights agreement.
On June 20, 2007, INCA issued a Convertible Promissory Note to Golden Ventures, LLC for $200,000 with a due date of June 20, 2008. The note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. The shares underlying the Note are covered under a registration rights agreement.
In October 2007, INCA issued a Convertible Promissory Note to Plato & Associates, LLC for $50,000 with a due date of June 20, 2008. The note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. The shares underlying the Note are covered under a registration rights agreement.
In October 2007, INCA issued a Convertible Promissory Note to Golden Ventures, LLC for $50,000 with a due date of June 20, 2008. The note is convertible into shares of INCA’s common stock at a forty percent discount to the market price of the Company’s stock or $0.50 per share, whichever is lower. The Note contains 4.99% ownership cap provisions. The shares underlying the Note are covered under a registration rights agreement.
In connection with the Acquisition, INCA entered into employment agreements with Stacy Josloff to serve as Chief Executive Officer and Chief Financial Officer and with Stephanie Hirsch to serve as President and Secretary. The initial terms of the agreements are five years, with an option to renew for an additional five-year period. Pursuant to the agreements, Josloff and Hirsch are to receive an annual base salary of $65,000. In addition to the base salary, Josloff and Hirsch are eligible for an annual bonus payment at the end of each fiscal year. The bonus is granted in the sole discretion of the Company’s board of directors and is based upon the Company’s performance and productivity. Bonus compensation may be paid to Josloff and Hirsch in the form of cash, stock options, or a combination thereof. Josloff and Hirsch are eligible for insurance benefits, reasonable expenses, and five (5) weeks of paid vacation in each calendar year.
Immediately following the closing of the Acquisition, under the terms of the Securities Exchange Agreement, INCA assumed subordinated convertible promissory notes previously issued by S2 (the “S2 Notes”) in the aggregate principal amount of $500,000, which, if and when converted, will convert into shares of INCA’s common stock. In association with the assumption of the S2 Notes, INCA issued an aggregate of 1,000,000 common stock purchase warrants to the holders of the convertible promissory notes which warrants were substituted for like warrants previously issued by S2. The warrants are exercisable for three years at an exercise price of $.50 per share and expire on October 31, 2009.
· Immediately following the closing of the Acquisition, an aggregate of $680,650 in INCA debt was converted by non-affiliates into 26,063,750 shares of its Common Stock at a conversion ratio of $.026 per share.
The 26,000,000 shares of INCA’s common stock issued to the former S2 Shareholders in connection with the Acquisition and the common stock purchase warrants issued to purchase 1,000,000 shares of INCA’s common stock were not registered under the Securities Act of 1933, as amended (the “Act”), in reliance upon the exemption from registration provided by Section 4(2) of the Act and Regulation D promulgated under that section, which exempt transactions by an issuer not involving any public offering. These securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. Certificates representing these shares contain a legend stating the same. The 26,063,750 shares of INCA’s common stock issued for conversion of debt were issued pursuant to an exemption from the registration provisions of the Act by reason of Section 4(2) of the Act
BTW, I have bought the products including
SURVIVOR + Emergency Pack, they are all excellent.
Thnx Ron, good 2 C U all found this undervalued play. I was told the CEO is speaking at a UNICEF event for the disaster preparedness industry leaders today. Cant find it online.
ZENTRAC BOARD APPROVES REVERSE SPLITAug 1, 2007
Pink Sheets News Service
Vancouver, Canada — Zentrac Technologies Inc. (ZTCT.PK) is pleased to announce shareholder and board approval of a 1 for 10 reverse split of all issued and outstanding shares. The authorized share capital shall remain the same. The appropriate documentation has been filed with NASDAQ Market Operations. It is expected that the effective date of the transaction will take place on the 15th. day of August 2007.
The new CUSIP number will be 98942T 309.
Approved on behalf of the Board of Directors
J. Roberts
_____________________
James Roberts
Chairman
info: jr@zentrac.com
www.zentrac.com
The above news release has been provided by the above company via Pink Sheets News Service. Issuers of news releases and not Pink Sheets are solely responsible for the accuracy of the such news releases.
ZTCT - Vancouver, Canada — Zentrac Technologies Inc. (ZTCT.PK) is pleased to announce shareholder and board approval of a 1 for 10 reverse split of all issued and outstanding shares. The authorized share capital shall remain the same. The appropriate documentation has been filed with NASDAQ Market Operations. It is expected that the effective date of the transaction will take place on the 15th. day of August 2007.
The new CUSIP number will be 98942T 309.
(note, this after 1 for 10 f/s Ex-Date: Aug 15, 2005
...just sellin paper...imo)
Approved on behalf of the Board of Directors
J. Roberts
_____________________
James Roberts
Chairman
info: jr@zentrac.com
www.zentrac.com
The above news release has been provided by the above company via Pink Sheets News Service. Issuers of news releases and not Pink Sheets are solely responsible for the accuracy of the such news releases.
Looks like
we've been.....
From the QUESTIONS ANSWERS & FEEBACK page
Q. How long will the filter last? How do I know when to change it?
A. Filters have been tested to 400 gallons for reductions - in the most extensive tests ever conducted on micro filters anywhere in the world. We reckon on a safety margin of use up to 150 gallons- 685 litres - Equivalent to 6 glasses of water every day for a year. When the filter is hard to draw water through simply replace. Any filters main enemy are sediments that coat the outside of the filter, eventually forming a protective coating; This prevents ingress into the filter and can be removed by using a cloth or micro cloth to lift out partculates. The golden rule is always draw cleanest looking water eg from a running source than still water and if you are in an area where water is questionable it is good practice to pre dose container - remember the filter has been designed to remove chemicals and purification taste and has been tested to 400 gallons.
Q. How do I deal with muddy turbid water?
All our filters have by design a pre filter structured dome that can be wiped clean.We would recommend where water muddy or overtly cloudy to draw and rest and then slowly pour into reservoir having left to settle for 10 minutes. This will preserve efficacy of filter and applies to all filter systems. We also recommend where water very cloudy or muddy maintainable pre filter pads that can be used on inline filters or a simple sock end and elastic band in our canteens and bottle systems. Some of our water bags have inbuilt pre filters.
Q. How can you be so sure of effectiveness of filters?
A. Tests, Tests and more tests! Our Filters are built to ISO specification-and will always be made in USA. Not all competitors are. Our filters have a 2 micron absolute micron size. Without absolute pore size you are not that well protected. Many competitors use carbon granules that channel and effectively perform like a split paper bag allowing shedding contaminants straight into the user! Most of our competitors tests are based on 1.0 litre contaminant testing and predicted outcomes made from these. We have tested our filters worldwide not just in our own facilities - more importantly through International quality and testing standards; These include tests at independant laboratories both in the commercial and Government sector for their effectiveness against disease carrying viral causatives, removal of chemicals and metals and sediments - mostly recently to stringent UK MoD Forces specification. Ask anyone else for their full test reports - We publish ours. Over 2 million filters are in use around the world and used by Disaster Relief Teams and Forces personnel.
Our filter tests are based on their ability to trap AND retain contaminants up to recommended levels though have been tested to exceed these.
Q. I've heard bacteria can grow in filters?
A. Unlike competitors we have worked hard to make all our micro filters resist bacterial growth by adding silver and other ingredients. In addition our 'All in One' filters contain a devitalization device. We have never had a return of filters with disease causative bacteria. Good practice dictates dosing the main reservoir with chlorine or iodine to keep this element clean, the purified water passes through filter too.
Q. How do I treat water that might be questionable and contain viral disease causatives in it?
A. Our 'All in One' filters contain pre purification filters,a purification device, post purification filter and post purification medias proven up to 600 litres in UK Government tests over 3 months and 150 separate tests. We used live disease causatives to prove our systems as a stand alone product when used as directed.
Good practice dictates occasional pre dosing of pre filter reservoir with steritab or similar purification to keep this free of micro organisms and causatives. The micro filter is designed to remove these purification chemicals and provide clean tasting water- Safe to drink.
Our extra silverated filters come with an anti viral kit as standard and operate to same specification as our 'All in One' purification and micro filters as above.
Q. What tests did you conduct to exceed UK MoD specification?
A. We tested up to 600 litres in UK Government tests over 3 months and 150 separate tests. We used live disease causatives to prove our systems as a stand alone product when used as directed. These included testing for operational field use and proving as a stand alone product for removal of viral waterborne causatives including Hepatitis, Polio, Cholera, Leptospirosis -(Bilhazia), Weils' disease- Norwark. Further tests conducted for Anthrax- All with 99.9999% reductions. Additional tests proved systems removal of Cryptosporidium cysts and Giardia, e-coli and e-faecalis to 99.99%. without pre dosing source water with purification biocide.
Other tests were proving the systems ability to UK MoD specification to remove any pre-dosed chemicals such as Steri chlor tabs or Iodine purification and provide safe clean drinking water. Additionally we passed Pcb's , Voc's , metals including lead and alumminum, pesticides and herbicides and suspended solids. These were the most thorough tests on mico filtration and purification systems anywhere in the world.
Q. I occasionally travel overseas on holiday but want to save bottled water costs - What system do you recommend?
A. We would recommend extra silverated filter system either 'Traveller' sipper hydration Bottle or 'Explorer' canteen or our extra silverated inline system if you are using a Camelbak or other hydration reservoir device. We supply you with a handy small anti viral dropper kit if you are ever in a questionable water area that will treat 150 litre water. Remember these filters alone will remove chemical taste and suspended solids, chemicals and metals in water delivering safe dirnking water without adding purification. They will also remove cryptosporidium, giardia and e-coli without purification. Their life expectancy and filtration ability is proven way beyond that of a jug filter system. They are easy to use and will save you a small fortune in bottled water!
Q. Can I use these for multi use ie occasionally?
A. Yes- Our filter systems are designed to be used as multi use devices - simply disconnect filter and air dry naturally then store until next needed.
Q. I serve in UK forces and am being posted overseas . We receive purified potable water at base but the water often tastes foul- full of chlorine. We also carry Camelbak hydration systems but again the taste of my water is revolting and when away on operational duties I have to draw questionable water from streams rivers or pond. We do pre dose hydration reservoir with steri chlor tablets when away from base supplies- (often for days on end), and I am drinking horrible tasting water . Am I doing any harm drinking all these purification chemicals and what system do you recommend?
A. Ingesting purification chemicals is not good on a taste basis, and what you may be submitting your body to absorb. Breaking tablets is not easy to measure purification dose or store the remaining part tablet. Our filters are designed to remove purification chemicals and taste associated with these and will also remove chemicals, viral causatives and even Anthrax if this is used in theatre of war.Added to this is that some cryptosporidium is gaining resistance to chlorine.
We have conducted tests on our purification systems ability to remove to WHO standards over recommended life of filter. We have designed and tested a new inline Eliminator 'All in One' micro purification and filtration system exceeding UK Government specification.
It can be used as a stand alone product and is the only system in the world proven to do so to UK MoD specification. Good practice dictates occasional pre dosing of reservoir to keep reservoir clean.
Additionally to our 'Eliminator' Inline systems we have fitted Non spill' Quick fit and release' mechanism enabling you to clip in the filter in under 2.0 seconds or remove at will and replace even with a gloved hand. The connect fittings can be multi used or transfered. Where water is guaranteed safe and clean to taste the great bonus is that your hydration tube can be simply reconnected and your hydration system used as normal.
Drawing water on demand through your bite tube is easy and this system can also be used to operate as a Gravity feed system - simply hang up reservoir release drink tube and bite valve and up to 800 mls micro purified and filtered safe drinking water a minute is delivered - without effort.
The 'Eliminator' is robust,discrete and can be dropped from 5 metres without damage. It is also is lightweight @ 125 gms. Quite simply the best system in the world - proven and used by other service personnel worldwide. Our systems are 'All in One ' systems. Easy to use, lightweight and FULLY proven unlike some competitors with their limiting claims. Ours are also substantially better value. Camelbak do NOT make a system in any way similar or in performance or value.Eliminator 'All in One' system with Clip in/out quick release system is just £39.95 for a complete kit.
Any questions? info@drinksafe-systems.co.uk
For UK MoD Ministry Defense tests: NLS Laboratory- UK 2005
'Method tests and evaluation to cover all areas of source water contamination Organic, Metal, Inorganic, Microbiological and Aesthetics were implemented and the filters efficacy to reduce levels of contaminants tested. Tests conducted to provide evidence of the filter's efficacy as a stand alone system. 'All in One' filter system 150 seperate tests June-August 2005 Inorganic Compounds:Up to 99.17% OCB's PCBs >96.7% Metal compounds up to 94.8% Turbidity Up to 87.20% VOC's Up to 94.2% Microbiological: Cryptosporidium 99.92% E-Coli Greater than 99.9999% E.Faecalis Greater than 99.9991% Waterborne virus causatives: up to 99.9999% Anthrax :Greater than 99.9995%
Test on No.1 Silverated filter system.'Removed 100% of Cryptosporidium and Giardia Cysts in test..... from a reservoir known to contain these micro biological organisms. Pathcentre Water Examination Laboratory Nedlands Western Australia. Accredited by National association testing laboratories (NATA) to ISO 17025 Wel method MWM017 Based on USA method EPA 1623 (April 2003 ) No chlorine or iodine used .
Tests carried out on No2. All in One Filter system( iodinated sleeves and filter). Bacteria using E. coli after 15 minutes showed a 2-3 log reduction in numbers (around 99.5%) removal and 6 log reduction at 30 minutes (99.9999% reduction) . Iodine will reduce bacteria such as E.coli by 6 log (99.9999%) within 2 minutes and poliovirus 3-4 logs (99.95%) after 10 minutes at iodine levels of 1.0-1.5 parts per million. Test Report: Infectious and Tropical diseases .London School of Hygiene and Tropical Medicine. (2nd October 2000)
"I spent 6 weeks in 12 African countries ... and have had no health problems at all. I have never known anything that can filter out micro organisms as this filter does. It is unique. I was amazed and am grateful. - E. Baron, University professor. Brigham Young University
"Without a single occurrence of tummy upset or related symptom. Not only were the team confident in the filters performance but were also impressed by the total omission of taste from water which would normally have to be treated by filtering, sterilising and boiling to make safe."
- M.G. Helliwell Lt Cmdr, HMS Sultan Royal Navy Survival School (Everest Trek 2000)
"..... Following the devastation of Hurricane Mitch... These filters saved our lives. I'm sure in two ways: firstly by giving us peace of mind .... secondly providing the pure H2O we were able to drink." - Steve Chandler MD. Kaiser Permanente Hematology/Oncology (1999)
"Thank you for keeping our intestines happy." - Robyn Bennacasa and Ian Adamson, Team Saloman Eco Challenge Race
"... From the moment the bottle was demonstrated to me I was sold on it ... at 9700ft, our headcamp, my friends' expensive $140.00 failed to the point of disintergration ... leaves you worn out from pumping water through the dense ceramic filter ... I grabbed my bottle, and in no time had filtered all the water we could need."
- Euan MCleod, Idaho USA
"My husband and I recently returned from a trip in North West Nicaragua. We were really impressed with your product, in fact it became a vital piece of equipment in our work at the clinic. We know it works." - Liz Brookes RMN RGN LNWCH
" During the 25 day trek to the Everest region of Nepal, water consumption was very high and dehydration a major concern. The ability to utilize any available water source was therefore an excellent way to reduce our dependence on prepared water ... It was safe, very convenient and all gained confidence in their use as the expedition progressed."
- UK Supreme Commandos
"Just a note to thank you for your help and to let you know what good you have done with your filtration bottles. The thousand bottles were passed out to all the relief workers in Acapulco, and I believe we have not seen one case of dysentery at the med-evac centre, where our workers are normally treated." - Carolina Jones RN, Director of relief efforts - La Cruz Roja Nacional de Mexico
"... the bottles were used daily to purify water from public water supply sources, as well as mountain streams and rivers. Not only did they work effectively and prevent any of us from getting sick, but their ease of use made drinking the recommended necessary daily water amount as simple as filling the bottle." - Steve Whitmeyer, Boston University
"I am totally convinced this is an essential piece of kit for anyone, professional or amateur, who has to survive on natural water supplies. The flexibility of not having to carry heavy loads of water, but just filling the bottle from a stream and in minutes enjoying clean drinking water WITHOUT any chemical taste,was superb ...... I would recommend it, without reservation, to anyone seriously involved in or considering outdoor pursuits." - UPH Ltd. UK
Found a new website for Seychelle SYEV ...
http://www.drinksafe-systems.co.uk
some items that caught my eye....
Proudly invented and Made in USA .
Used in more than 55 countries
Safe water from any inline hydration system at half the cost of any other product on the market.
As used by Special Forces , Forces personnel. Rescue teams, surveillance teams and Police forces around the world.
Save a fortune on Designer label water - Also suitable for foreign travel Incredibly robust -Easy to use. Includes tap adaptor For Disaster relief / Emergency base camps. Excellent for Emergency family use where water threat greatest . Simple to use .
Tested by numerous US government health departments including the London School of Hygiene and Tropical Medicine
and numerous other Worldwide government health departments.
In use by International Red Cross, Service personnel worldwide and US Disaster Relief Team
Contains additional in-built purification device
Fits discreetly in hydration packs- For Camelbak and other premium in- line hydration systems
In developing countries 80% of all diseases are spread by the contamination of unsafe water -WHO World Health Organisation
MTRM - Salford Georgia and Compound Capital Limited Agree To Acquire All Shares of Common Stock of Metromedia International Group, Inc. for $1.80 per Share
Cash Tender Offer for Shares of Common Stock of Metromedia International Group, Inc. to Commence by July 20, 2007
Jul 17, 2007 2:27:00 PM
Copyright Business Wire 2007
CHARLOTTE, N.C.--(BUSINESS WIRE)--
Metromedia International Group, Inc. (the "Company" or "Metromedia") (currently traded as: (PINK SHEETS: MTRM) - Common Stock, and (PINK SHEETS: MTRMP) - Preferred Stock) today announced that the Company entered into an agreement pursuant to which affiliates of Salford Georgia ("Salford") and Compound Capital Limited ("Compound") will make a tender offer, expected to commence before July 20, 2007, for all issued and outstanding shares of Metromedia common stock at a purchase price of $1.80 per share in cash. The purchase price of $1.80 per share represents a premium of approximately 29% over the closing price of shares of Metromedia common stock on July 16, 2007, the last trading day before the public announcement of the tender offer, and a premium of approximately 18% over the average closing price of the shares for the last 12 months.
CaucusCom Ventures L.P. ("Parent"), a British Virgin Islands limited partnership and a joint venture between Salford and Compound, and CaucusCom Mergerco Corp. ("Purchaser"), a Delaware corporation and wholly-owned subsidiary of Parent, entered into a definitive merger agreement with Metromedia, dated as of July 17, 2007, pursuant to which Purchaser will make a tender offer to acquire any and all of the issued and outstanding shares of Metromedia common stock, par value $0.01, for $1.80 per share in cash, net to the seller. The merger agreement also provides that, subject to the satisfaction of certain conditions, the tender offer will be followed by a second-step merger, in which Purchaser will be merged with and into the Company, with the Company as the surviving corporation. In the merger, all shares of Metromedia common stock not tendered in the tender offer will be canceled and converted into the right to receive the price of $1.80 per share in cash. The Company's 7.25% cumulative convertible preferred stock will remain outstanding following consummation of the tender offer and the merger. In connection with the merger, holders of Metromedia common stock and preferred stock will have the right to seek appraisal under Delaware law.
In addition to customary conditions, consummation of Purchaser's tender offer is subject to the condition that, as of the expiration date of the tender offer, there shall have been tendered at least 63,300,000 shares of common stock (which represents approximately 61.3% of the presently issued and outstanding shares of Metromedia common stock), plus all shares of common stock issued or issuable between the date of the merger agreement and the expiration date of the tender offer in response to any election to exercise an option or warrant or to convert shares of Metromedia's preferred stock into shares of common stock. Purchaser is permitted on a single occasion to lower the minimum number of shares described above to a level not less than 56,182,474 shares of common stock (which represents approximately 54.4% of the presently issued and outstanding shares of Metromedia common stock) plus 50% of all shares of common stock issued or issuable between the date of the merger agreement and the expiration date of the tender offer in response to any election to exercise an option or warrant or to convert shares of Metromedia's preferred stock into shares of common stock.
If, following consummation of the tender offer, Purchaser owns at least 90% of the outstanding shares of Metromedia common stock or is able to exercise an option granted by the Company to purchase additional shares of Metromedia common stock authorized but not issued as of the completion of the tender offer in a number which would bring Purchaser's ownership to at least 90% of the outstanding shares of common stock, then Purchaser will immediately undertake the second-step merger pursuant to Delaware's short-form merger statute. If these conditions are not satisfied, Purchaser will nonetheless own more than a majority of the outstanding shares of Metromedia common stock and, as promptly as reasonably practicable following the Company becoming current with respect to the filing of all outstanding periodic reports required to be filed with the U.S. Securities and Exchange Commission (the "SEC"), or having received a waiver from the SEC with respect thereto, the Company will prepare and file with the SEC a proxy or information statement with respect to the merger and will hold a meeting of its stockholders for the purpose of obtaining approval of the merger agreement and the merger. In the meeting, Purchaser's vote of its majority of Company common stock would be sufficient to secure such approval.
The tender offer will be open for 20 business days following its commencement, subject to Purchaser's rights and obligations to extend the tender offer in certain circumstances. In addition, if Purchaser reduces the minimum tender condition as described above and, as of the expiration date of the tender offer, the total number of shares of common stock acquired by Purchaser is less than the original minimum tender condition, then Purchaser is obligated to commence a subsequent offering period of not less than ten or more than twenty business days to acquire additional shares of common stock. During such subsequent offering period, shares of common stock not tendered during the initial offering period may be tendered to Purchaser for the same offer price per share paid for shares tendered during the initial offering period.
The transaction was approved by Metromedia's Board of Directors. In connection with the execution of the merger agreement, Purchaser, Parent and certain Metromedia stockholders holding, beneficially or of record, approximately 35,581,072 shares of common stock in the aggregate, this being approximately 34.5% of all common shares presently issued and outstanding, entered into a tender and support agreement, dated as of July 17, 2007, pursuant to which such Metromedia stockholders have agreed, among other things and subject to certain termination rights, to tender their shares of common stock pursuant to the tender offer and to vote their shares of common stock in favor of the merger and against any alternative acquisition proposal.
Mark Hauf, Chairman, Chief Executive Officer and President of Metromedia, said: "We are delighted with the value that the Salford/Compound group's proposal presents to the Company's common stockholders. Following initial presentation of this proposal some months ago, the Company's board of directors undertook a comprehensive process to assess alternatives for maximizing stockholder value. We concluded that the agreement with the Salford/Compound group offers excellent value to Metromedia's common stockholders and delivers such value quickly by means of the cash tender offer. Furthermore, although the Salford/Compound group does not presently contemplate a tender for the Company's preferred stock, if the merger is consummated, our preferred stockholders will have the right to seek appraisal of the fair value of preferred shares. In all other respects, the present rights of preferred stockholders are not altered, and we believe that Metromedia's financial prospects will not be adversely affected by the Salford/Compound transaction."
Evercore Group L.L.C. is acting as financial advisor to Metromedia, and Paul, Weiss, Rifkind, Wharton & Garrison LLP and Richards, Layton & Finger, P.A. are acting as its legal counsel. Debevoise & Plimpton LLP and Potter Anderson & Corroon LLP are acting as legal advisors to the Salford/Compound group.
Metromedia will file a current report on Form 8-K with the SEC containing a copy of the merger agreement that Metromedia has entered into with the Salford/Compound group. The current report on Form 8-K will be available on the SEC's website, www.sec.gov, and on Metromedia's website, www.metromedia-group.com.
About Salford Georgia and Compound Capital Limited
Salford Georgia is the local Georgian office of Salford Capital Partners Inc., an international private equity and investment management firm focused on developing markets; primarily the Commonwealth of Independent States and Central and Eastern Europe. Salford's investment philosophy is to focus on industries where there is growth/consolidation and companies with restructuring potential. Through a strong local market presence, Salford actively participates in the management of the companies it invests in.
Compound is an international private investment firm based in Bermuda. Compound's investment strategy is to identify investment opportunities within developing markets or out of favor sectors of the economy. An inherent part of the Compound investment activity is to take an active part in the ongoing management of its investments.
About Metromedia International Group, Inc.
Through its wholly owned subsidiaries, Metromedia International Group, Inc. owns interests in several communications businesses in the country of Georgia. The Company's core businesses include Magticom, Ltd., Georgia's leading mobile telephony operator located in Tbilisi, Georgia, Telecom Georgia, a well-positioned Georgian long distance telephony operator, and Telenet, a Georgian company providing Internet access, data communications, voice telephony and international access services.
IMPORTANT NOTICE: This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any of Metromedia's equity securities. The tender offer described herein has not yet been commenced. On the commencement date of the tender offer, an offer to purchase, a letter of transmittal and related documents will be filed with the SEC, mailed to record holders of shares of the Company's common stock and made available for distribution to beneficial owners of shares of the Company's common stock. The solicitation of offers to buy Metromedia common shares will only be made pursuant to the offer to purchase, the letter of transmittal and related documents. When they are available, stockholders should read those materials carefully because they will contain important information, including the various terms of, and conditions to, the tender offer. When they are available, stockholders will be able to obtain the offer to purchase, the letter of transmittal and related documents without charge from the SEC's Website at www.sec.gov or from Mellon Investor Services, the information agent for the tender offer. Stockholders are urged to read carefully those materials when they become available prior to making any decisions with respect to the tender offer.
Metromedia will file a solicitation/recommendation statement with the SEC in connection with the tender offer, and, if required, will file a proxy statement or information statement with the SEC in connection with the second-step merger following consummation of the tender offer. Metromedia's stockholders are strongly advised to read these documents if and when they become available because they will contain important information about the tender offer and the merger. Metromedia's stockholders will be able to obtain a free copy of the solicitation/recommendation statement and the proxy statement or information statement as well as other filings containing information about Metromedia, the tender offer and the merger, if and when available, without charge, at the SEC's Internet site (www.sec.gov). In addition, copies of the solicitation/recommendation statement, the proxy statement or information statement and other filings containing information about Metromedia, the tender offer and the merger may be obtained, if and when available, without charge, by directing a request to Metromedia International Group, Inc., Attention: Chief Financial Officer, 8000 Tower Point Drive, Charlotte, North Carolina 28227 or by phone at (704) 321-7380.
Forward-Looking Statements
This news release contains certain forward-looking statements made as of the date hereof based only on current information and expectations that are inherently subject to change and involve a number of risks and uncertainties, including in particular those that could cause actual results to differ materially from those anticipated, projected or implied, including, among other things, risks relating to the expected timing of the completion and financial benefits of the tender offer and the merger. Various factors beyond the control of the Company, Salford Georgia or Compound Capital Limited could cause or contribute to such risks and uncertainties. This also includes such factors as are described from time to time in the SEC reports filed by the Company, including the Current Annual Report on Form 10-K for the year ended December 31, 2004, and its most recently filed Form 8-K reports (dated January 6, 2005, February 9, 2005, February 17, 2005, March 9, 2005, March 23, 2005, April 19, 2005, April 20, 2005, June 7, 2005, June 17, 2005, July 12, 2005, July 18, 2005, July 25, 2005, July 28, 2005, August 3, 2005, August 10, 2005, September 8, 2005, September 19, 2005, January 31, 2006, March 8, 2006, March 15, 2006, March 17, 2006, May 11, 2006, May 18, 2006, June 26, 2006, July 14, 2006, August 8, 2006, August 15, 2006, August 22, 2006, September 27, 2006, October 2, 2006, October 10, 2006, October 24, 2006, October 25, 2006, October 30, 2006, November 16, 2006, November 17, 2006, November 20, 2006, November 30, 2006, December 5, 2006, December 13, 2006, December 15, 2006, December 18, 2006, March 1, 2007, April 26, 2007, May 1, 2007, May 25, 2007, May 30,2007, June 27, 2007 and June 28, 2007). The Company, Salford Georgia and Compound Capital Limited are not under, and each of them expressly disclaims any, obligation to update the information in this news release, for any future events or otherwise.
Please visit Metromedia's website at www.metromedia-group.com.Source: Metromedia International Group, Inc.
----------------------------------------------
Metromedia International Group
Inc.
Ernie Pyle
704-321-7380
Executive Vice President Finance
Chief Financial Officer and Treasurer
investorrelations@mmgroup.com
or
Mellon Investor Services
888-823-4441 or collect: 201-680-6578
ITTV - Interactive Television Networks, Inc. Announces Sale of ITVN, Inc. Assets
Jul 17, 2007 2:09:00 PM
IRVINE, Calif., July 17 /PRNewswire-FirstCall/ -- Interactive Television Networks, Inc. (OTC Bulletin Board: ITTV) announced today that on July 11, 2007 its wholly owned subsidiary, ITVN, Inc., a Nevada corporation ("ITVN"), has entered into an agreement to sell substantially all of its assets to BroadShift Inc., a corporation existing under the laws of the Province of Ontario, Canada ("BroadShift"). The total purchase price is approximately U.S. $11 million, payable in cash and shares of BroadShift, Inc. stock. Details of the asset sale are available in Interactive Television Network's Form 8-K filing with the Securities and Exchange Commission filed on July 17, 2007.
ITVN, Inc. is a wholly-owned subsidiary of Interactive Television Networks, Inc., a Nevada corporation. Interactive Television Networks conducts substantially all of its operations through ITVN, and substantially all of the operating assets related to the operations of its digital video internet distribution business are owned by ITVN. BroadShift is a Canadian aggregator and distributor of narrowcast Internet protocol television.
This press release contains forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the network and products of Interactive Television Networks, Inc. and ITVN, Inc. The closing of the sale of ITVN's assets is subject to a number of conditions, including the release of all liens on the assets and the completion of a public offering by BroadShift, Inc.. All forward-looking statements are based upon information available to Interactive Television Networks, Inc. on the date the statements are first published. Interactive Television Networks, Inc. undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Interactive Television Networks, Inc.
----------------------------------------------
media@itvn.com
1-866-988-4988
ESMC - Escalon(R) Receives 510(k) Clearance from FDA for Distribution of TRILOGY(R) Analyzer
Chemistry Analyzer Complements Augments Escalon's Suite of Hematology Products
Jul 17, 2007 12:30:00 PM
WAYNE, Pa., July 17 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) announced today that its Drew Scientific business unit received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the new TRILOGY Analyzer. TRILOGY, a multifunction analyzer used in determination of analytes in body fluids, is an open system intended for clinical use in a professional setting for use with various chemistry assays. The analyzer is currently on display at the 2007 AACC Annual Meeting and Clinical Lab Expo held in San Diego, CA. Drew Scientific plans to commence shipments of the product in the United States immediately.
"We are excited about broadening our product portfolio and having FDA clearance of the new multi-purpose analyzer in time for the opening of the AACC conference this week," commented Richard J. DePiano, Chairman and Chief Executive Officer. "The TRILOGY system augments our existing hematology base business providing Drew Scientific with the ability to offer turnkey solutions in both chemistry and hematology."
TRILOGY was designed for the quantitative determination of glucose, creatinine and urea nitrogen in serum. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia and idiopathic hypoglycemia, and of pancreatic islet call carcinoma. Creatinine measurements are used in the diagnosis and treatment of renal diseases and in monitoring renal dialysis. Urea nitrogen measurements are used in the diagnosis and treatment of certain renal and metabolic diseases. TRILOGY includes an optional Ion Selective Electrodes (ISE) module for the measurement of sodium, and chloride in serum and urine. These measurements are used to monitor electrolyte balance and in the diagnosis and treatment of diseases involving electrolyte imbalance.
Drew Scientific is a diagnostics company specializing in the design, manufacture and distribution of instruments for blood cell counting and blood analysis. Drew Scientific is focused on providing instrumentation and consumables for the physician office and veterinary office laboratories. Drew Scientific also supplies the reagent and other consumable materials needed to operate the instruments.
Founded in 1987, Escalon develops markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products as well as vascular access devices. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. Escalon seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of Escalon's distribution capabilities, although any such partnerships or acquisitions may not occur. Escalon has headquarters in Wayne, Pennsylvania and manufacturing operations in Long Island, New York, New Berlin, Wisconsin, Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.
Note: This press release contains statements that are considered forward- looking under the Private Securities Litigation Reform Act of 1995, including statements about Escalon's future prospects. They are based on Escalon's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether Escalon is able to:
-- implement its growth and marketing strategies, improve upon the
operations of Escalon's business units, including the integration of
Drew Scientific's and MRP's operations, the reorganization of the Drew
Scientific's business and the integration of any acquisitions it may
undertake, if any, of which there can be no assurance;
-- implement cost reductions;
-- generate cash; and
-- identify, finance and enter into business relationships and
acquisitions.
Other factors include uncertainties and risks related to:
-- new product development, commercialization, manufacturing, product
liability and market acceptance of new products,
-- marketing acceptance of existing products in new markets, the
continuity of royalty revenue, litigation and non-recurring expenses;
-- research and development activities, including failure to demonstrate
clinical efficacy;
-- delays by regulatory authorities, scientific and technical advances by
Escalon or third parties;
-- introduction of competitive products;
-- third party reimbursement and physician training, and
-- general economic conditions.
Further information about these and other relevant risks and uncertainties may be found in the Company's report on Form 10-K, and its other filings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.
SOURCE Escalon Medical Corp.
----------------------------------------------
Richard J. DePiano
Chairman and CEO of Escalon Medical Corp.
+1-610-688-6830; or Joseph Calabrese of Financial Relations Board
+1-212-827-3772
AVGO - Avicena to Proceed to Confirmatory Phase III Amyotrophic Lateral Sclerosis (ALS) Trial
Jul 17, 2007 12:18:00 PM
PALO ALTO, Calif., July 17 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that it met with the Food and Drug Administration (FDA) and will proceed with a confirmatory Phase III trial of its lead drug candidate, AL-02, for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease).
Two completed Phase III studies led by Dr. Jeffrey Rosenfeld of the Carolinas ALS Center and North East ALS Consortium (NEALS) demonstrated a positive trend towards increased survival at 9 months. The results of the studies are pending publication. Further, Avicena will be analyzing the data at the 18-month time point to confirm a longer term survival benefit. These data will be used to support a new Phase III study which is planned to commence in 2008. The new Phase III study will be designed to evaluate AL-02's potential to increase survival.
"We are very pleased with the FDA's feedback and we eagerly anticipate moving AL-02 forward into a confirmatory Phase III trial during the first quarter of next year," stated Belinda Tsao-Nivaggioli, Chief Executive Officer of Avicena. "Given the severity of this unmet medical need, the advancement of our lead ALS drug candidate represents significant progress for Avicena and our collaborators, NEALS and the Carolinas ALS Center. We hope to duplicate the pooled results of two prior studies which demonstrated AL-02's potential to increase survival of patients afflicted with ALS."
ABOUT ALS
ALS is a neurodegenerative disease that attacks the motor neurons of the brain and spinal cord that are responsible for voluntary muscle movement. As these motor neurons degenerate, their ability to send impulses to the muscle fibers is compromised. The progressive degeneration of motor neurons eventually leads to neuron death resulting in the brain's inability to initiate or control muscle movement. Once a patient's muscles no longer receive the messages that they require to function, the muscles begin to atrophy. With an incidence rate of approximately 1 in 10,000, ALS affects roughly 30,000 Americans at any given time. Each year, approximately 5,600 new cases of ALS are diagnosed.
ABOUT AVICENA
Avicena Group, Inc. is a Palo Alto, California-based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS. Near term, Avicena intends to initiate a Phase III trial in Huntington's disease to accompany the ongoing Phase III trial in Parkinson's disease. Avicena's science is well-established and its products are safe and well-tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.
SAFE HARBOR
This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from our Annual Report on Form 10-KSB for the year ended December 31, 2006, and other descriptions in the company's public filings with the Securities and Exchange Commission for a discussion of such risks, including the company's need for additional funds, the company's dependence on a limited number of therapeutic compounds, the stage of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. Avicena does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.
Contact:
The Ruth Group (on behalf of Avicena Group, Inc.)
Sara Ephraim (investors)
(646) 536-7002
sephraim@theruthgroup.com
Janine McCargo (media)
(646) 536-7033
jmccargo@theruthgroup.com
SOURCE Avicena Group, Inc.
----------------------------------------------
Investors
Sara Ephraim
+1-646-536-7002
sephraim@theruthgroup.com
or Media
Janine McCargo
jmccargo@theruthgroup.com
both of The Ruth Group
for Avicena Group
Inc.
IMHI - Endavo Media and Global Digital Broadcast Sign Global Partnership
Joint Marketing Agreement Merges IPTV and Online Entertainment for Global Television Distribution
Jul 17, 2007 9:52:00 AM
ATLANTA, GA -- (MARKETWIRE) -- 07/17/07 -- Endavo Media and Communications, Inc., an Integrated Media Holdings, Inc. (OTCBB: IMHI) subsidiary, has signed a joint marketing and network agreement with Global Digital Broadcast Ltd (GDB), a world leader in IPTV.
The new strategic agreement enables both Endavo Media and GDB to deliver both IPTV and online entertainment delivery strategies, as an integrated solution, to independent TV channel owners and any content owner seeking large-scale distribution. For consumers, the integrated platform means being able to access your favorite home TV channels and on-demand programming from anywhere in the world.
Under the joint marketing agreement, GDB will market Endavo Media's online delivery platforms to its IPTV customers. In exchange, Endavo will offer GDB's IPTV set-top-box solution to television channel owners and programmers seeking alternative television channel distribution. The companies are already in joint talks with multiple independent channel and content owners regarding the integrated strategy which will represent significant new sources of revenue for both companies.
GDB co-founder and spokesman David Wray comments, "Our venture with Endavo further expands the opportunities of both companies internationally and proves once again that there is a huge demand for such IPTV services. GDB is more than happy to offer Endavo's services into the UK and European markets where our brand is already very strong. Likewise, it is great to enable the GDB platform on the Endavo backbone throughout the US."
In addition to the Joint Marketing Agreement, the companies have also agreed to hand off content delivery network traffic inside each other's network territories, which provides additional revenue for both companies and extends each other's network presence globally. Endavo says that within the next two years it expects to generate over $500,000 annually just from the basic network revenue from the agreement.
"The days of the big guys making all the programming decisions and all the money from them are over," stated Paul D Hamm, Endavo CEO. "Independent content producers and programmers are realizing that they have the ability to attract more viewers on their own through the web and alternative platforms and to keep more of the profits. We are excited about partnering with such a world-class IPTV provider in GDB and making that concept a reality."
About GDB
Based in Hove, East Sussex, UK, Global Digital Broadcast operates an IPTV delivery network with a large client base of content providers and channel owners. GDB hosts independent channels from local TV and regional programming, to multi-cultural and international streaming and hosts content from over 70 countries. Clients include: politics show "18 Doughty Street" and the Local Government Channel; niche sports channels such as America's National Football League Alumni, Suzuki, TVScuba, TV Freestyle and Ryman's football league; music channels Invincible and Make it or Break it TV; niche and specialist Suncastv, Faithglobe and Dave Courtney TV; IPTV information streaming from Future of Broadcast and community channels TVBrighton, TVWorthing and TVChichester. Also specialising in channel creation, GDB's convergent technologies allow for a simple set-up process and the GDB audio visual entertainment centre (AVEC set-top box) is pre-programmed with both GDB's own middleware and existing channels. For more information, please visit www.globaldigitalbroadcast.com.
About Endavo Media
Endavo Media and Communications, Inc. provides a digital media broadcast and management system that enables individuals and large companies alike to distribute content to broad audiences through the Internet, IPTV, and mobile devices. Endavo also offers the tools to promote, monetize, and monitor digitally broadcasted programming through advertising, subscription and pay-per-view models. For more information, please visit www.endavomedia.com or call 877-843-7242 ext. 81 for sales or ext 800 for investor relations.
About I-Media Holdings
Integrated Media Holdings, Inc. (OTCBB: IMHI), headquartered in Atlanta, GA, invests in, builds and operates innovative digital communications and media technologies businesses that provide multiple forms of distribution for entertainment, media, and communications services over the Internet and broadband networks. For more information, please visit www.i-mediaholdings.com, call (678) 222-3445 or email info@i-mediaholdings.com
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, technical development risks, seasonality and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contact:
For Integrated Media Holdings, Inc., Atlanta
Will Wellons
407-462-2718
Will@Wellonscommunications.com
For Global Digital Broadcast
David Wray
david@gdbtv.com
Telephone: +44 (0) 1273 774 800
I will pass...thnx
ok...point is it was over 2 bucks then down to .0001 r/s 500000/1...how can this be trusted.
post number 17
Its from this board when it was MGWB...dont u remember?
Care to comment on this then?
http://investorshub.advfn.com/boards/read_msg.asp?message_id=21260379
manny, lies r ok though?
AEHI - Alternate Energy Holdings (AEHI) Gets County Green Light to Move Forward on Idaho Nuclear Plant
Jul 17, 2007 9:15:00 AM
LYNCHBURG, VA -- (MARKETWIRE) -- 07/17/07 -- Alternate Energy Holdings (PINKSHEETS: AEHI) announced that the Owyhee County Commission voted unanimously to accept an application from AEHI to construct a nuclear plant near Grand View, Idaho. The project previously obtained the necessary land and funding. Local and federal processes for the plant will now run concurrently, with the Nuclear Regulatory Commission approval being the last major milestone before construction. AEHI Chairman and CEO Don Gillispie stated, "This is a key step in the process to obtain cost-effective, safe, clean and reliable power for the county, Idaho and the region."
About Idaho Energy Complex Corporation (www.idahoenergycomplex.com)
The Idaho Energy Complex, a holding of AEHI, is a proposed $3.5 billion commercial nuclear power plant/bio-fuel generation facility to be constructed on a designated site near Grand View, Idaho. The electricity provided by the nuclear plant would be sufficient to power Idaho's growing needs and allow the elimination of fossil fuels for current power production. Additionally, excess heat from the nuclear reactor would be used to produce ethanol and methane from local crops and agricultural waste.
About Alternate Energy Holdings, Inc. (www.alternateenergyholdings.com)
Alternate Energy Holdings actively acquires private green energy companies, as well as develops and markets innovative clean energy sources. Current projects include nuclear construction, bio-fuel generation, a safe and effective system for removing carbon dioxide from coal and natural gas plants emissions, and marketable lightning harvesting technology for electricity production.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Although AEHI believes that the assumptions underlying the forward-looking statements contained herein are reasonable, there can be no assurance that the forward-looking statements included in this press release will prove accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion should not be regarded as a representation that the objective and plans of AEHI will be achieved.
Add to Digg Bookmark with del.icio.us Add to Newsvine
For More Information:
Email Contact
Investor Relations Inquiries:
540-586-7470
Email Contact
Careful on over doing the catnip...lol
SDTH - ShengdaTech Begins Production of New NPCC Lines
Adds 40,000 Metric Tons Capacity
TAIAN CITY, China, July 17 /Xinhua-PRNewswire-FirstCall/ -- ShengdaTech Inc. ('ShengdaTech' or 'The Company') (Nasdaq: SDTH) a leading manufacturer of nano precipitated calcium carbonate (NPCC) and coal-based chemical products in the People's Republic of China ('PRC'), today announced it completed the addition of 40,000 metric tons of annual NPCC capacity at its factory in Xianyang City, Shanxi Province.
ShengdaTech added two new lines, each with 20,000 metric tons of annual capacity, to its factory at Shengda Industrial Park. The new lines utilize the Company's advanced cost-efficient membrane diffusion technology which lowers production costs of NPCC particles by 5-7% compared to the traditional ultra-gravity method. The membrane diffusion method also provides better quality NPCC particles, providing a broader range of market applications. ShengdaTech is currently developing a number of new NPCC applications in various plastics.
ShengdaTech invested approximately $10 million for the equipment, which increases annual capacity at the factory to 100,000 metric tons and total annual capacity to 130,000 metric tons. The Company expects the new lines to operate at full capacity by November 2007. Assuming full utilization and using current prices after value added tax for NPCC products, the additional 40,000 metric tons of production capacity is equivalent to approximately $15 million in potential additional revenues to ShengdaTech.
'We are very pleased with our progress to date in expanding our capacity. We opened our new factory at Shengda Industrial Park with 60,000 metric tons of capacity in the fall of 2006 and quickly ramped up to full capacity by December 2006. Our new factory is located close to high quality limestone and uses cost-efficient membrane diffusion technology which have the combined effect of reducing our production costs of NPCC particles by 30%,' commented Mr. Xiangzhi Chen, CEO of ShengdaTech. 'We are excited about opportunity for our NPCC products as we develop new applications and expand into overseas markets. We expect NPCC to continue contributing to our revenue growth and gross margin in the future, in fact, as previously announced, our plans call for another expansion of NPCC capacity as early as December of this year.'
About ShengdaTech, Inc.
ShengdaTech is engaged in the business of manufacturing, marketing and selling a variety of nano-precipitated calcium carbonate ('NPCC') products and coal-based chemicals for use in various applications. The Company converts limestone into NPCC using its proprietary technology. The unique chemical and physical attributes make NPCC a valuable ingredient in tires, paints, polyvinyl chloride ('PVC') building materials and other products. NPCC enhances the durability of many products by increased strength, heat resistance, and dimension stabilization. The Company is also engaged in the manufacture and sale of coal-based chemical products namely ammonium bicarbonate, liquid ammonia, melamine and methanol. The Company markets and sells its coal-based products mainly for chemical fertilizers and raw materials in the production of organic and inorganic chemical products, including formaldehyde and pesticides.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the tire industry, changes in composition of tires, ability to attract new customers, ability to increase our product's applications, ability of our customers to sell products, cost of raw material, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission.
For more information, please contact:
Crocker Coulson, President
CCG Elite
Tel: +1-646-213-1915
Email: crocker.coulson@ccgir.com
Leslie Richardson, Financial Writer
CCG Elite
Tel: +1-646-213-1915
Email: leslie.richardson@ccgir.com
SOURCE ShengdaTech Inc.
Source: PR Newswire (July 17, 2007 - 7:30 AM EST)
News by QuoteMedia
www.quotemedia.com
YTBL - YTB International Announces Effective Date for Common Stock Reclassification and Split
Jul 17, 2007 8:00:00 AM
WOOD RIVER, Ill., July 17 /PRNewswire-FirstCall/ -- YTB International, Inc. (OTC: YTBL.PK) ("YTB" or the "Company"), a provider of Internet-based travel booking services for travel agencies and home-based independent representatives in the United States, today announced July 31, 2007 as the effective date of the Company's common stock reclassification and stock split.
YTB previously announced the shareholder approval of an amendment and restatement of the Company's Certificate of Incorporation to authorize the issuance of two classes of common stock, Class A and Class B, and to increase the Company's total authorized capital. As of the effective date, shareholders will receive two shares of Class B, and one share of Class A, common stock in exchange for each share of existing common stock held as of the close of trading on the effective date.
If shareholders hold unrestricted shares through a brokerage account or in street name, then no action needs to be taken on their part, as the new shares will automatically be credited to their brokerage account in replacement of existing shares. If existing shares are held in record name, then shareholders will receive a transmittal letter from the Company's transfer agent, American Stock Transfer & Trust Company. This mailing will occur on or about the July 31 effective date. Shareholders that receive the transmittal letter will be required to fill out any documentation included as instructed and mail it back, along with their existing common stock certificates, to the transfer agent at the address provided. Once the transfer agent receives the requested information, along with existing common stock certificates, the new Class A and Class B shares will be issued.
As of July 17, 2007, YTB International had 38.9 million existing shares outstanding. Following the reclassification and share split, the Company will have approximately 38.9 million shares of Class A common stock outstanding, and approximately 77.8 million shares of Class B common stock outstanding.
Further information on both the reclassification and split can be found in the Company's 2007 Definitive Proxy Statement on Schedule 14A, filed with the Securities & Exchange Commission on April 24, 2007.
About YTB International
YTB International, Inc. provides Internet-based travel booking services for travel agencies and home-based independent representatives in the United States, Puerto Rico, and the US Virgin Islands. It operates through three subsidiaries: YourTravelBiz.com, Inc., YTB Travel Network, Inc., and REZconnect Technologies, Inc. YourTravelBiz.com division focuses on marketing on-line travel agencies through a nationwide network of independent business people, known as "Reps." YTB Travel Network division establishes and maintains travel vendor relationships, books travel transactions of on-line travel agents (RTAs, now numbering over 100,000), collects travel payments and licensing fees, and processes travel commissions. Each RTA sells travel through a personalized Internet-based travel Website. The REZconnect Technologies division builds online reservation systems for suppliers within the travel industry.
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. The Company undertakes no obligation to update forward-looking statements to reflect subsequently occurring events or circumstances.
This document is available on the KCSA Worldwide Website at www.kcsa.com.
Investor Contacts:
Garth Russell / Yemi Rose
KCSA Worldwide
212-896-1250/ 212-896-1233
SOURCE YTB International, Inc.
----------------------------------------------
Investors
Garth Russell
+1-212-896-1250
or Yemi Rose
+1-212-896-1233
both of KCSA Worldwide
for YTB International
Inc.
Nefertiti and the Lost Dynasty Tonight,
Siemens CT Scanner Reveals Mysteries inside Egyptian Relic
German Researchers Using a SOMATOM(R) Sensation 64 Computed Tomography Scanner Will Present Their Work Tonight on the National Geographic Channel Special: Nefertiti and the Lost Dynasty
Jul 16, 2007 2:50:00 PM
Copyright Business Wire 2007
MALVERN, Pa.--(BUSINESS WIRE)--
The bust of Nefertiti stored at Berlin's Altes Museum, is one of the most renowned works of ancient Egyptian sculpture. Fifteen years ago, a computed tomography (CT) scan of the bust revealed that a second structure was hidden inside. This structure was presumed to be a cast of the subject's face, but the image resolution was too poor to be conclusive. With recent advances in CT scanning, researchers called for a repeat scan to document the structure within the bust. Results of the scan, which was conducted using a Siemens Medical Solutions (www.usa.siemens.com/medical) SOMATOM(R) Sensation 64-Slice CT, are included in a National Geographic Channel special that will premiere tonight.
"I have always been interested in the secret carried inside that bust. But it is also very difficult and hazardous to examine ancient artifacts without damaging them," said Prof. Dietrich Wildung, director of the Egyptian Museum in Berlin.
With the help of one of Siemens' highest resolution CT scanners, Prof. Wildung and Alexander Huppertz, MD, head of the Imaging Science Institute in Berlin, as well as the National Geographic team, were able to X-ray the bust without damaging it.
"Our technology is intended to improve the medical care of patients around the world. However, we are happy to contribute to efforts that explain the mysteries of archaeology," said Bernd Montag, president, Siemens Medical Solutions, Computed Tomography. "We scanned the mummy of Tutankhamen two years ago and we are now helping with another ancient Egyptian treasure."
Researchers who conducted the original CT scan of Nefertiti assumed that the bust's limestone core would more accurately approximate the subject's face. After the facial mold was cast, the limestone core was coated with plaster and painted. Prof. Wildung said that the portrait on the coat of plaster is not very representative and that the bust itself is of greater value in determining the features of the subject.
Nefertiti and the Lost Dynasty, premieres tonight at 9 p.m. on the National Geographic Channel, check local listings for more information.
About the Imaging Science Institute, Berlin
The Imaging Science Institute Charite Berlin - Siemens (ISI) is a research institute for imaging diagnostics. Since October 2004, the newest technologies of diagnostic imaging, such as computed or magnetic resonance tomography are developed further in a clinical environment under the scientific leadership of Prof. Bernd Hamm in Berlin Mitte in cooperation with the Charite - Universitatsmedizin Berlin and Siemens Medical Solutions.
About Siemens Medical Solutions
Siemens Medical Solutions of Siemens AG (NYSE: SI) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics - such as Diagnostic Products Corporation and Bayer Diagnostics - mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30). Further information can be found by visiting www.usa.siemens.com/medical-pressroom.
Source: Siemens Medical Solutions
----------------------------------------------
Siemens Medical Solutions
Mark Palacio
610-448-1477
mark.palacio@siemens.com
MDII - MDI Attains Ownership of Learn Safe(TM) and Other Security Programs under the ''Safe Initiatives'' Brand
Jul 16, 2007 1:01:00 PM
Copyright Business Wire 2007
SAN ANTONIO--(BUSINESS WIRE)--
MDI, Inc. (NASDAQ: MDII), the leading provider of Unified Technology(TM) solutions for the security industry has today announced the following significant events:
* Ownership of LearnSafe and Other Safe Initiatives
On July 11, 2007, MDI attained ownership of the "Safe Initiatives" brand portfolio formerly under Stratis Authority, Inc. The transaction included the unique program financing model that is designed to deliver affordable alternative funding methods to end-users requiring comprehensive safety and security programs. MDI's new brand portfolio will consist of Learn Safe(TM), Work Safe(TM), Play Safe(TM) and Live Safe(TM). Further details on the formal launch of these brands by MDI will follow at a later date.
As part of the transaction, the rights to trademarks and tradenames associated with the Safe Initiatives, including the name "Stratis", have been assigned to MDI. It is the decision of MDI management to discontinue all use of the name "Stratis" immediately. All "Safe Initiative" operations previously handled from the Stratis Florida office will be administered out of MDI's corporate headquarters in San Antonio, Texas.
The following URLs, phone and fax numbers have been assigned to MDI and will be redirected to the appropriate MDI personnel in San Antonio, Texas:
-- www.learnsafe.org (including all corporate email addresses)
-- www.stratisauthorityinc.com (including all corporate email
addresses)
-- The Learn Safe toll free number - (866) 423-1740
-- General telephone number - (407) 423-1740; and
-- Fax number - (407) 805-0338
MDI has begun the integration of the new "Safe Initiatives" business into the MDI business infrastructure. MDI management, under the direction of CEO and President J. Collier Sparks, will manage this integration.
* Resignation of Mr. James M. Vandevere from the MDI Board of Directors
Mr. James M. Vandevere resigned as a Director of MDI, effective July 11, 2007. The company has no present intention to fill the vacancy.
* MDI Suit Against Ecomatrix Funding and Minh Phan Settled
On June 15, 2007, the suit brought by MDI against Ecomatrix Funding, Inc. and Minh Phan was resolved to the parties' mutual satisfaction. All litigation between the parties has been dismissed. MDI continues to own all of the ASL assets and rights it acquired in January 2006, including all of the ASL intellectual property rights, software, trademarks, goodwill, customer and supplier agreements. The California office formerly occupied by ASL has been transferred to MDI's San Antonio, Texas headquarters. Effective February 2007, Minh Phan ceased to be associated with MDI.
About MDI, Inc.
MDI (NASDAQ: MDII) manufactures security technology solutions designed to protect people, facilities and assets. These solutions are unified by ONE Technology. ONE Technology unifies security point products, systems and subsystems into a common management platform. Far beyond the Integrated Security Management software promoted by industry competitors, ONE delivers an open architecture environment that adapts each individual application and device into its platform - promoting global collaboration as ONE system. The MDI product family currently protects over 8 million alarm points across the globe for many of the world's most recognized organizations including Microsoft, MBNA Worldwide, John Deere, Pepsi, FBI, TSA, Fidelity Investments, Bureau of Engraving & Printing, American Express, Department of Defense, IRS, Disney, The Smithsonian, MIT and San Diego Unified School District to name a few. The company has received numerous industry awards for their security technology including Frost & Sullivan's Security System Technology Leadership Award and the Security Industry Association's Best Integrated Product Award for 2006. For more information on MDI or its diversified line of products and professional services, please visit www.mdisecure.com.
Forward-Looking and Cautionary Statements
Except for historical information and discussions contained herein, certain statements included in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.
Source: MDI, Incorporated
----------------------------------------------
MDI
Incorporated
Investor Relations Contact:
Richard A. Larsen
210-582-2664
Richard.Larsen@mdisecure.com
or
Media Contact:
Michael M. Garcia
210-477-5400
Mike.Garcia@mdisecure.com
RBCF (Float listed at 587k) on bounce watch.
SGLS - Signature Enters Negotiations With a Chinese Media and Advertising Group
Jul 16, 2007 12:19:00 PM
CASSELBERRY, FL and CHAMPLIN, MN -- (MARKETWIRE) -- 07/16/07 -- Signature Leisure, Inc. (OTCBB: SGLS) announced today that the company has entered into negotiations for Signature to provide consulting services to a Chinese media and advertising group.
The potential client's management has expressed the desire to obtain a listing as a public company on a U.S. based OTC equities exchange. Signature has opened negotiations with management whereby Signature would provide consulting services to guide the media group's management through the process. Additionally, Signature is negotiating to provide Investor Relations services for the Chinese media group once the company obtains a listing.
The Chinese company is a media and advertising holding Company based in Guangzhou, the third most populous city in China. The company's goal is to achieve additional growth through acquisitions and intends to target various acquisition candidates in China that possess both high revenue and high net profit margins.
About Signature Leisure, Inc. (OTCBB: SGLS) -- Signature Leisure, Inc. is a publicly traded company trading on the OTC Bulletin Board under the symbol SGLS. For more information about Signature Leisure, Inc., please visit the Company's website at http://www.signatureleisure.com
This press release contains certain "forward-looking" statements, as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. Statements, which are not historical facts, are forward-looking statements. The company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are estimates reflecting the company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by the company.
This press release is provided for information purposes only and is not intended to constitute an offer to sell or a solicitation of an offer to buy securities.
Contact:
Signature Leisure, Inc.
Stephen W. Carnes
407-599-2886
info@signatureleisure.com
MDII - MDI Awarded Multi-State Blanket Purchasing Contract from Texas Education Service Center to Supply Systems to Schools, Universities, Cities and Counties
State Markets Served By Security Contract Award Include TX, AZ, AR, NM and OK
Jul 16, 2007 11:34:00 AM
Copyright Business Wire 2007
SAN ANTONIO--(BUSINESS WIRE)--
MDI, Inc. (NASDAQ:MDII), the leading provider of Unified Technology(TM) solutions for the security industry today announced that it has been awarded a contract by the largest Education Service Center in Texas to provide security systems as part of their direct purchasing network which specializes in a multitude of school-based solutions for K-12 and college campuses. The new security contract will be used by public and private schools, colleges, universities, cities, counties and other government agencies in the States of Texas, Arizona, Arkansas, New Mexico and Oklahoma to purchase products and services without having to undergo the costs of establishing a competitive bidding process.
The list of end-user organizations that are now able to purchase security systems through MDI's multi-state vendor contract include:
-- Over 1,100 School Districts Across the Aforementioned Five
States
-- Over 225 Private and Charter Schools
-- Over 40 Junior Colleges, Colleges and Universities
-- 19 Additional Regional Service Centers Across the State of TX
-- 100 County Governments
-- 160 City Governments
-- 150 State Agencies, Other Local Governments and Non-profit
Organizations
The contract was awarded to MDI in accordance with a "point system" which compiled scores based on multiple factors including; past performance in the government security arena, professional services capabilities, suitability and quality of technology products, competitive pricing and additional offerings and programs available to support the extensive client roster. The contract was awarded for an initial period of one year with an option to renew annually for an additional four years if agreed to by the awarding agency and MDI. There is a contract maximum of five years.
Products, services and training from MDI partners including Nortel, ASSA ABLOY and the SBS Group will be included on the schedule of offerings. The contract will be managed and orders will be fulfilled from MDI's San Antonio, TX headquarters.
-- MDI Signs Marketing Agreement with School Board AssociationMDI has also announced that it has entered into a marketing contract with the States School Board Association to promote the Learn Safe(TM) Initiative, as a platinum-level sponsor, in a series of conferences to be held this year. These select conferences are directed towards district decision makers such as School Administrators, Superintendents and School Board Officers.
Among the most notable promotional engagement on the list, the Learn Safe(TM) program will be the exclusive sponsor and featured presenter for a special industry solutions conference that will bring together key decision makers from 50 of the largest school districts, in a small seminar format, to discuss safety and security challenges within their school campuses.
Additional information about specific conference dates and locations will be released at a later date.
About MDI, Inc.
MDI (NASDAQ:MDII) manufactures security technology solutions designed to protect people, facilities and assets. These solutions are unified by ONE Technology. ONE Technology unifies security point products, systems and subsystems into a common management platform. Far beyond the Integrated Security Management software promoted by industry competitors, ONE delivers an open architecture environment that adapts each individual application and device into its platform - promoting global collaboration as ONE system. The MDI product family currently protects over 8 million alarm points across the globe for many of the world's most recognized organizations including Microsoft, MBNA Worldwide, John Deere, Pepsi, FBI, TSA, Fidelity Investments, Bureau of Engraving & Printing, American Express, Department of Defense, IRS, Disney, The Smithsonian, MIT and San Diego Unified School District to name a few. The company has received numerous industry awards for their security technology including Frost & Sullivan's Security System Technology Leadership Award and the Security Industry Association's Best Integrated Product Award for 2006. For more information on MDI or its diversified line of products and professional services, please visit www.mdisecure.com.
Forward-Looking and Cautionary Statements
Except for historical information and discussions contained herein, certain statements included in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this document, other than statements of historical fact, that address activities, events or developments that management expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements represent our reasonable judgment on the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "project," "forecast," "plan," "may," "will," "should," "expect" and other words of similar meaning. Investors should not rely on forward-looking statements because they are subject to a variety of risks and uncertainties and other factors that could cause actual results to differ materially from the Company's expectation. Additional information concerning risk factors is contained from time to time in the Company's SEC filings. The Company expressly disclaims any obligation to update the information contained in this release.
Source: MDI, Incorporated
----------------------------------------------
MDI
Incorporated
Investor Relations:
Richard A. Larsen
210-582-2664
Richard.Larsen@mdisecure.com
or
Media :
Michael M. Garcia
210-477-5400
Mike.Garcia@mdisecure.com
my favorite post on this board...
Posted by: mannyman
In reply to: None Date:5/26/2006 2:19:01 PM
Post #of 877
This just out
Bill Gates of Micrsoft has agreed to join the board of advisers of Magicweb, Inc. trading as MGWB
How about that?
(this before the 500000 to 1 r/s)
shaking my head
CMBC - Calypte Reports Positive Results of Aware(TM) HIV-1/2 Oral Fluid Rapid Test Evaluation at 3rd Annual South African AIDS Conference
Jul 16, 2007 8:30:00 AM
LAKE OSWEGO, Ore., July 16 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTCBB: CBMC), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced today the results and positive social implications of a field evaluation of its Aware(TM) HIV-1/2 OMT (oral fluid) rapid test in the Republic of South Africa . These results were recently presented in a poster at the 3rd South African AIDS Conference in Durban last month. Posters are scientific research papers (in poster presentation form) accepted by a conference for the education of its attendees, typically displayed in a Poster Section on the conference floor.
The field evaluation was conducted on 600 clients of unknown HIV status at two busy Voluntary Counseling and Testing ("VCT") clinics in South Africa. The expected HIV prevalence rate was 30-40%; overall, 44% of the clients tested positive. The poster reported that "the results obtained on OMT were comparable with results on serum, and were statistically significant."
Study nurses responsible for the collection of samples described OMT (oral fluid test) collection as "easy to do", and preferred the non-invasive oral fluid collection method to the blood collection currently in use. Laboratory personnel found the test procedure simple to perform and results easy to interpret. "This assay may be a suitable alternative for VCT practices," was the poster's conclusion.
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "We have long known the accuracy of the Aware(TM) HIV-1/2 oral fluid rapid test. The usage studies that are now being reported are focusing on the social aspects of such a test and we are pleased that there is strong sentiment for adopting oral fluid testing. While changing long-established blood collection practice to the OMT method is a process, we believe we are gaining momentum in making oral fluid an acceptable alternative to blood testing. The recent approval of our oral fluid test in India and the subsequent interest we are seeing from the government, military and private sectors is very encouraging in this regard."
Johannes Viljoen, MBChB, FC Path (SA) Viro, at the College of Health Sciences of the University of KwaZulu-Natal, Durban, South Africa and principal investigator presenting this poster noted, "We specialize with individuals living in rural settings of South Africa. In South Africa there are ongoing public health and media campaigns to increase public awareness and uptake of HIV testing in an attempt to curb the spread of the epidemic. We anticipate that offering a non-invasive rapid test may quite possibly result in an enhanced uptake of testing, mostly as a result of it being more acceptable and painless, even more so for children. In our study, the technique was clearly preferred over finger-sticks by the health care providers."
Dr. Pravi Moodley, Acting Head of the Department of Virology at the University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa and a co-author of the poster commented, "The sampling of oral fluid for HIV antibody rapid testing in resource constrained settings has advantages over the conventional finger-prick blood which is currently used for HIV antibody rapid testing. The obtaining of an oral fluid sample is much simpler since a community health worker requiring minimal training will be able to obtain the sample. It is also much safer since no sharps and sharps containers are necessary, obviating the need for intensive health and safety training which may unnecessarily consume financial and human resources in already resource constrained settings."
Further, our field evaluation of Calypte's Aware(TM) HIV-1/2 OMT Rapid Test showed excellent correlation with blood samples," concluded Dr. Moodley.
About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the AwareTM HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.
Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.
Company Contact:
Richard Brounstein, Executive Vice President
(971) 204-0282
email: rbrounstein@calypte.com
Investor Relations Contact:
Tim Clemensen,
Rubenstein Investor Relations
Phone: (212) 843-9337
email: tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
----------------------------------------------
Company: Richard Brounstein
Executive Vice President
+1-971- 204-0282
rbrounstein@calypte.com
or Investor Relations: Tim Clemensen
Rubenstein Investor Relations
+1-212-843-9337
tclemensen@rubensteinir.com
WTVI - Wi-Fi TV to Deliver First Streaming Movie to iPhone Today in Breakthrough Which Frees up Space on iPhone and Expands Movie Distribution
Jul 13, 2007 9:15:00 AM
NEWPORT BEACH, CA -- (MARKETWIRE) -- 07/13/07 -- Wi-Fi TV Inc. (PINKSHEETS: WTVI), a small and little known public company that has consistently broken technological barriers ushering in the delivery of video over the Internet since 1995, announced today that it will be offering the public the first ever delivery of a streaming movie to the iPhone from a website (www.iPhoneWi-FiTV.com).
Wi-Fi TV Breaks iPhone� Movie Memory Barrier:
The importance of showing streaming movies on the iPhone is that the iPhone has a limited and non-expandable memory that can only hold a certain number of songs, videos and other information. Movies are the most memory intensive form of entertainment and depending on the other content a user chooses to save on their iPhone, there may only be room for a single movie, or no movie at all, to download in an individual iPhone. Unlike other plans announced to deliver movies to the iPhone, Wi-Fi TV does not require a movie to be downloaded and stored in the iPhone memory, but rather Wi-Fi TV streams the movie, which takes up no memory space in the iPhone.
Public Can Watch Movie On iPhone Today:
Today at www.iPhoneWi-FiTV.com Wi-Fi TV is offering a free streaming movie which can be viewed in the iPhone as an example of its technology and as a preview to a large number of movies it will be offering as both streaming and downloadable content to iPhones and other Internet enabled devices. To the best of the knowledge of Wi-Fi TV Inc., no other company prior to today has offered the public a movie that streams to the iPhone.
Potential For New Ad Revenue Model With Free Movies:
Since Wi-Fi TV will be adding brief video advertisements at the beginning of each of its movies, the ability of Wi-Fi TV to deliver streaming movies to the iPhone, and many other devices, has great potential value in revenue generation for the company.
"The entire Wi-Fi TV Sales Team will benefit from our Company's unique and industry leading ability to deliver streaming movies to the iPhone," said Joe Soto, Wi-Fi TV Global Vice President.
Breakthrough Is Part of Wi-Fi TV Strategic Plan:
"Following a directive of our Founder and Chairman, the Wi-Fi TV technical team has spent many hours of research on the iPhone and has moved to quickly establish itself as a source of video entertainment content to iPhone�, iPod� and AppleTV�. Today's industry leading beta test for the public is indicative of where Wi-Fi TV is going in multimedia content delivery," said Thomas Hagstrom, a technical consultant to Wi-Fi TV Inc. "It is just the beginning of the content we will offer," Mr. Hagstrom added.
How To Watch Free Movie Today:
To watch a movie on your iPhone, streaming and for free, go to www.iPhoneWi-FiTV.com.
About Wi-Fi TV:
Wi-Fi TV(TM) is a pioneer of TV on the Internet. Wi-Fi TV Inc. has long touted the coming convergence of TV and the Internet, and provided the first online movie in December 1995. The Wi-Fi TV website is the only place on the Internet where you can watch hundreds of TV stations and chat with others watching the same program in a live chat box directly under the viewing screen, and get breaking news for each country and category listed, and download a dialer and make free phone calls and host live video parties all on one website.
Wi-Fi TV Inc. provides Social Internet TV(TM), a new generation TV delivery platform that has a geographic sphere out-distancing any traditional cable or over-the-air TV broadcaster. Wi-Fi TV memberships are free at www.Wi-FiTV.com and include such perks as free online phone calls and free chat and free online parties.
The Company was launched in 1995 and has been publicly traded since November 1997, and has been a pioneer in the delivery of video and books over the Internet.
Press Relations:
Wi-Fi TV Inc. has opened a content and technology demo room for the press in Newport Beach, California. For further information contact Colby Marceau, (949) 716-9397, info@wi-fitv.com.
Forward-Looking Statements
Any statements made in this press release which are not historical facts contain certain forward-looking statements; as such term is defined in the Private Security Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. The actual results of the specific items described in this release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward-looking statement. Wi-Fi TV and Social Internet TV are trademarks of Wi-Fi TV Inc. and all rights pertaining to these names are reserved. iPhone�, iPod� and AppleTV� are registered trademarks of Apple. There is no relationship between Apple and Wi-Fi TV, and none is implied. This press release shall not be deemed a general solicitation.
Contact:
Colby Marceau
(949) 716-9397
Email Contact
RVNG - Raven Gold Corp. announces today that a second load of concentrate totalling approximately 6.5 tonnes have been delivered to the smelter in Torreon
Jul 13, 2007 9:02:00 AM
LAS VEGAS, July 13 /PRNewswire-FirstCall/ - Raven Gold Corp. (OTCBB: RVNG) (the "Company"), is pleased to announce that a second load of concentrate totalling approximately 6.5 tonnes have been delivered to the smelter in Torreon with payments expected to be in approximately 30 days.
The mill continues to be fine tuned and is now generating recovery rates of approximately 83% for Silver and 85% for Gold. Recent head grades have been averaging approximately 1.9 grams Gold and 223 grams Silver. Values for this shipment average approximately 700 grams Gold and 38 Kilos Silver per tonne of Concentrate.
Blair Naughty, President of Raven Gold Corp. commented that, "We are very excited to be able to ship the second load of concentrate to the smelter in Torreon, this will in-turn generate revenues for Raven Gold, Corp. and will be used for exploration of other high grade gold and silver deposits."
About La Currita
The La Currita Groupings includes 4 mines, a 300 ton/day operating floatation mill and stockpiled ore. The La Currita mine was in steady production from 1983 until 1998. A diamond drilling exploration program conducted in 1998 indicated grades of 2.59 g/t Au and 200 g/t Ag. Existing mines and mineralized structures hold potential to increase tonnage through systematic exploration. The area surrounding La Currita has numerous mines and recent substantial discoveries. Adjacent to the La Currita holdings, Palmarejo recently merged with Coeur d'Alene Mines Corporation and Bolnisi Gold NL, in a transaction valued at approximately US$1.1 billion, creating the world's leading primary silver producer. In addition, about 20 miles to the SE is the 170,000 ounce/year Glamis Gold's El Sauzal gold mine and 40 miles to the North is Gammon Lake Resource's Ocampo Gold-Silver Project with a projected 270,000 gold-equivalent ounces/year.
About Raven Gold Corp.
Raven Gold Corp. is an international gold mining company, with exploration and development projects. Raven's mandate is to initiate an aggressive acquisition policy, focusing on under-explored to advanced stage exploration gold deposits in North and South American Countries. Raven is focused on becoming a low cost gold producer.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained herein which are not historical are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies or products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.
CONTACT: Raven Gold Corp., Investor Relations, 1-877-31-RAVEN (1-877-317-2836), Email: ir@ravengold.com, Website: www.ravengold.com
SOURCE Raven Gold Corp.
----------------------------------------------
Raven Gold Corp.
Investor Relations
1-877-31-RAVEN (1-877-317-2836)
Email: ir@ravengold.com
Website: www.ravengold.com
BIOF - BioFuel Energy Retires $30.0 Million of Debt
Jul 12, 2007 6:51:00 PM
DENVER, July 12 /PRNewswire-FirstCall/ -- BioFuel Energy Corp. (Nasdaq: BIOF) announced today that the underwriters of its recently completed initial public offering had exercised their full over-allotment option, purchasing 787,500 additional shares of common stock. The shares were purchased at the $10.50 per share offering price, resulting in $7.7 million of additional proceeds to the Company. With the over-allotment, a total of 10,287,500 new shares were sold by the Company. Of these shares, 6,037,500 were sold to the public and 4,250,000 were sold simultaneously to the Company's three largest pre-existing shareholders. Outstanding shares now total 33.3 million. Net proceeds from the offerings approximated $100.3 million. Earlier this week, the Company retired $30.0 million of its subordinated debt with offering proceeds, leaving $20.0 million of subordinated debt outstanding.
BioFuel Energy is a development stage company currently engaged in constructing two 115 million gallons per year ethanol plants in the Midwestern corn belt. The Company's goal is to become a leading ethanol producer in the United States by acquiring, developing, owning and operating ethanol production facilities.
Contact: David J. Kornder For more information:
Executive Vice President & http://www.bfenergy.com
Chief Financial Officer
(303) 592-8110
dkornder@bfenergy.com
SOURCE BioFuel Energy Corp.
----------------------------------------------
David J. Kornder
Executive Vice President & Chief Financial Officer of BioFuel Energy Corp.
+1-303-592-8110
dkornder@bfenergy.com
ENCY - Encysive Pharmaceuticals Provides Update for Thelin (Sitaxsentan Sodium)
Jul 13, 2007 7:00:00 AM
2007 PrimeNewswire, Inc.
HOUSTON, July 13, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced that the Company and officials from the U.S. Food and Drug Administration (FDA) held a formal Class A preliminary dispute resolution meeting regarding the June 15th approvable letter and the status of our New Drug Application (NDA) for Thelin(tm) (sitaxsentan sodium). Several members of Encysive's internal and external regulatory team attended the meeting with the FDA. In addition, Robyn J. Barst, M.D., Professor of Pediatrics at Columbia University College of Physicians and Surgeons, and Director, New York Presbyterian Hospital Pulmonary Hypertension Center and a principal investigator in the STRIDE-2 trial, attended the meeting.
The Company originally submitted an NDA for Thelin to treat pulmonary arterial hypertension (PAH) in February 2005. In the June 15th approvable letter, the FDA concluded that Encysive's clinical development program for Thelin did not demonstrate significant evidence of efficacy needed for approval.
This meeting complies with the FDA's guidance on dispute resolution requiring that a sponsor meet with the division reviewing its NDA prior to requesting formal dispute resolution. The Company expects to file a request for formal dispute resolution with the FDA in the near term.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: www.encysive.com.
The Encysive Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=843
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are: decisions by the FDA regarding whether and when to approve our NDA for Thelin(tm); unexpected delays in regulatory approval of Thelin(tm) by the FDA in the U.S. and our other products under development; the unpredictability of the duration and results of regulatory review of new drug applications and investigational new drug applications by the FDA; our estimate of the sufficiency of our existing capital resources; our ability to raise additional capital to fund cash requirements for future operations; the availability of sufficient funds to commercialize Thelin(tm) in the U.S. should it be approved by the FDA, as well as more specific risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion.
CONTACT: Encysive Pharmaceuticals
Investors:
Ann Tanabe, VP, Investor Relations and Corporate
Communications
(713) 796-8822
BMC Communications
Media:
Dan Budwick
(212) 477-9007 ext. 14
The Trout Group
Marcy Strickler
(646) 378-2927
GNTAD - (R/S) NASDAQ Grants Extension for Genta to Comply with Listing Requirements
Thursday July 12, 6:36 pm ET
Company Will Implement Reverse Stock Split to Retain Compliance
BERKELEY HEIGHTS, N.J., July 12 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced that the NASDAQ Listing Qualifications Panel has granted Genta's request for continued listing of its securities on The Nasdaq Global Market. The continued listing is subject to certain conditions, including the implementation of a reverse stock split by no later than July 13, 2007 and Genta's subsequent compliance with NASDAQ's $1.00 minimum bid price requirement for a minimum of ten consecutive business days.
ADVERTISEMENT
In order to retain compliance with listing requirements, Genta also announced today that its Board of Directors has approved a one-for-six reverse stock split of Genta's Common Stock, and that the split will be effective with the open of trading on July 13, 2007. At the annual meeting of shareholders held on July 11, 2007, Genta's shareholders approved a proposal authorizing the Board of Directors, in its discretion, to effect a reverse split of Genta's outstanding common stock at a ratio within a specified range. The reverse split will reduce the outstanding number of shares of Genta's Common Stock from approximately 184 million to approximately 31 million.
As a result of the reverse stock split, holders of certificates representing shares of "old" Genta Common Stock prior to the effective date have the right to receive, upon surrender of those certificates, "new" shares of Genta Common Stock at the ratio of one share of "new" Common Stock for every six shares of "old" Common Stock. No fractional shares will be issued in connection with the reverse stock split. Instead, holders of "old" shares who otherwise would have received fractional shares will receive an amount in cash equal to the value of such fractional shares based on the closing price of Genta's Common Stock on July 12, 2007.
Effective July 13, 2007, Genta's Common Stock will trade on The NASDAQ Global Market on a split-adjusted basis under the trading symbol "GNTAD". Genta's Common Stock will resume trading under the trading symbol "GNTA" on or about August 10, 2007.
Existing stockholders holding Genta Common Stock certificates will receive a Letter of Transmittal from the Company's transfer agent, BNY Mellon Shareowner Services, with specific instructions regarding the exchange of shares. Questions regarding this exchange process can be addressed by contacting BNY Mellon Shareowner Services at 1-800-777-3674 (or 1-201-680-6654 from outside the U.S.).
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (www.idispharma.com) on a program whereby both Ganite® and Genasense® are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:
-- the Company's ability to obtain necessary regulatory approval for
Genasense® from the U.S. Food and Drug Administration ("FDA") or
European Medicines Agency ("EMEA");
-- the safety and efficacy of the Company's products or product
candidates;
-- the Company's assessment of its clinical trials;
-- the commencement and completion of clinical trials;
-- the Company's ability to develop, manufacture, license and sell its
products or product candidates;
-- the Company's ability to enter into and successfully execute license
and collaborative agreements, if any;
-- the adequacy of the Company's capital resources and cash flow
projections, and the Company's ability to obtain sufficient financing
to maintain the Company's planned operations;
-- the adequacy of the Company's patents and proprietary rights;
-- the impact of litigation that has been brought against the Company and
its officers and directors and any proposed settlement of such
litigation;
-- the Company's ability to meet the conditions for continued listing on
the NASDAQ Global Market, including NASDAQ's $1.00 minimum bid price
requirement for a minimum of ten consecutive business days; and
-- the other risks described under Certain Risks and Uncertainties Related
to the Company's Business, as contained in the Company's Annual Report
on Form 10-K and Quarterly Report on Form 10-Q.
The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.
CONTACT:
For Genta Incorporated
Tara Spiess
TS Communications Group, LLC
(908) 286-3980
info@genta.com
--------------------------------------------------------------------------------
Source: Genta Incorporated
Woohoo, thats nice to see after,
04/11/2007 MGWB Magicweb Inc Common Stock MGWE Magicweb Inc New Common Stock 1-500,000 R/S **
this company burned a lot of folks already.